Omental Tissue Autograft in Human Recurrent Glioblastoma Multiforme (rGBM)

This single center, single arm, open-label, phase I study will assess the safety of laparoscopically harvested autologous omentum, implanted into the resection cavity of recurrent glioblastoma multiforme (GBM) patients.

Trial Details

NCT ID
NCT05979064
Phase
NA
Sponsor
Northwell Health
Status
RECRUITING
Cancer Type
Glioblastoma (GBM) Brain Cancer
Interventions
  • Laparoscopically harvested omental tissue autograft
Locations (sample)
  • New York, New York, United States|40.71427,-74.00597

Key Eligibility Criteria

  • Subject is a male or female 18 years of age or older.
  • Subject is undergoing planned resection of known or suspected GBM.
  • Subject has a Karnofsky Performance Status (KPS) 70% or greater.
  • Subject has a life expectancy of at least 6 months, in the opinion of the Investigator.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Glioblastoma (GBM) Brain Cancer Trials on Trialify →